Factor XIII Val 34 Leu: A novel association with primary intracerebral hemorrhage

Stroke

Volumn 29, Issue 4, 1998, Pages 813-816

  Catto, Andrew J ^a   Kohler, Hans P ^a   Bannan, Sally ^a   Stickland, Max ^a   Carter, Angela ^a   Grant, Peter J ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Factor XIII; Fibrin; Intracerebral hemorrhage; Mutation; Risk factors

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR;

ARTICLE; BRAIN HEMORRHAGE; CONTROLLED STUDY; CROSS LINKING; DISEASE ASSOCIATION; GENOTYPE; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RISK FACTOR; SINGLE STRAND CONFORMATION POLYMORPHISM; STROKE;

EID: 0031922936     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.4.813     Document Type: Article

References (14)

1. Grant PJ, Prentice CRM, Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. 3rd ed. Edinburgh, UK: Churchill Livingstone; 1994;54:1231-1254.
2. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
3. Resch KL, Ernst E, Matrai A, Paulsen HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med. 1992;117:371-375.
4. Fatah k, Silveira A, Tornvall P, Karpe F, Blombäck M, Hamsten A. Proneness to the formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost. 1996;76:535-540.
5. Sakata Y, Aoki N. Cross-linking of α2-plasmin inhibitor to fibrin by fibrin stabilizing factor. J Clin Invest. 1980;65:290-297.
6. Shen LL, Hermans J, McDonagh J, McDonagh RP, Carr M. Effects of calcium ion and covalent crosslinking on formation and elasticity of fibrin cells. Thromb Res. 1975;6:255-265.
7. Mikkola H, Syrjälä M, Rasi V, Vahtera E, Hamalainen E, Peltonen L, Palotie A. Deficiency in the α-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood. 1994;84:517-525.
8. Kohler HP, Stickland MH, Ossei-Gerning N, Carter AM, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost. 1998;79:8-13.
9. Hantano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ. 1976;54:541-553.
10. Catto AJ, Carter AM, Stickland MH, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost. 1997;77:730-734.
11. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-1526.
12. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost. 1995;74:842-847.
13. Mansfield MW, Stickland MH, Carter AM, Grant PJ. Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. Thromb Haemost. 1994;71:731-736.
14. Bamford J, Dennis MS, Sandercock P, Burn JPS, Warlow C. The frequency, causes and timing of death within 30 days of a first stroke: The Oxfordshire Community Stroke Project. J Neurol Neurosurg Psychiatry. 1990;53:824-829.